Clinical Outcomes With Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Insulin-Naïve and Previously Insulin-Treated Individuals With Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials.

Mushood AhmedAimen ShafiqHira JavaidHritvik JainAbdulqadir Jeprel NashwanQura Tul-AinJawad Basit

Published in: Endocrinology, diabetes & metabolism (2024)

Insulin icodec was associated with a reduction in glycated haemoglobin levels and higher time in range, with a similar safety profile as compared to insulin glargine U100. However, further evidence is still needed to reach a definitive conclusion.

Keyphrases

type diabetes
glycemic control
squamous cell carcinoma
physical activity
newly diagnosed